What is the most likely diagnosis and first-line management for a child or young adult presenting with sudden onset edema, nephrotic-range proteinuria (>3.5 g/24 h), hypoalbuminemia and hyperlipidemia?

Minimal Change Disease: Diagnosis and First-Line Management

Most Likely Diagnosis

In a child or young adult presenting with sudden onset edema, nephrotic-range proteinuria (>3.5 g/24 h), hypoalbuminemia, and hyperlipidemia, minimal change disease (MCD) is the most likely diagnosis, particularly in children aged 2-10 years. 1, 2, 3

Diagnostic Criteria

Confirming Nephrotic Syndrome

• Nephrotic-range proteinuria ≥3.5 g/24 hours in adults (or UPCR ≥3500 mg/g; ≥40 mg/h/m² in children) 1, 3
• Hypoalbuminemia <3.0 g/dL in adults (<2.5 g/dL in children) 1, 3
• Edema (periorbital, facial puffiness, lower extremity, or ascites) 1, 4
• Hyperlipidemia (elevated total cholesterol, LDL, triglycerides) 1, 2

Age-Specific Diagnostic Approach

Children aged 1-10 years with typical presentation:

• Kidney biopsy is NOT routinely indicated at initial presentation 3, 5
• Proceed directly to empiric corticosteroid therapy without biopsy 4, 5
• Biopsy is reserved for steroid-resistant cases, age <1 year or >12 years, macroscopic hematuria, hypertension, low C3 levels, or persistent renal failure 1, 4

Adults and children ≥12 years:

• Kidney biopsy is indicated to establish histologic diagnosis before initiating immunosuppression 3, 6, 5
• Exception: positive serum anti-phospholipase A2 receptor antibodies (diagnostic of membranous nephropathy) 3, 5

First-Line Management

Corticosteroid Therapy (Primary Treatment)

Initial regimen for children:

• Prednisone 60 mg/m²/day (maximum 60-80 mg/day) for 4 weeks, followed by alternate-day prednisone with gradual tapering 1, 7, 4
• 85-90% of children achieve complete remission with initial steroid therapy 4

Initial regimen for adults with biopsy-proven MCD:

• Prednisone 1 mg/kg/day (maximum 80 mg) OR alternate-day 2 mg/kg (maximum 120 mg) for minimum 4 weeks up to 16 weeks or until complete remission 2, 6, 7
• After remission, taper slowly over 6 months to complete total treatment course 2, 6

Critical Safety Caveat for ACE Inhibitors/ARBs

DO NOT start ACE inhibitors or ARBs in patients presenting with abrupt onset nephrotic syndrome suspected to be MCD—these drugs can cause acute kidney injury, especially in volume-depleted patients with MCD. 1

• Delay RAS inhibition until after immunosuppression is initiated and patient is stabilized 1
• Once appropriate, use ACE inhibitors/ARBs for persistent proteinuria despite immunosuppression 1

Supportive Management

Edema control:

• Dietary sodium restriction to <2.0 g/day (<90 mmol/day) 1
• Loop diuretics (furosemide) for moderate to severe edema 1, 8
• Add thiazide diuretics for synergistic effect in diuretic-resistant cases 1
• Avoid routine albumin infusions; reserve only for severe hypovolemia with hypotension 2, 4, 8

Thromboembolism prophylaxis:

• Consider prophylactic anticoagulation when serum albumin <2.0-2.5 g/dL AND additional risk factors present (proteinuria >10 g/day, BMI >35, immobilization) 2, 6, 9
• Warfarin is preferred anticoagulant (target INR 2-3); avoid direct oral anticoagulants due to unpredictable pharmacokinetics with heavy proteinuria 2, 9

Infection prevention:

• Pneumococcal vaccination (increased risk of Streptococcus pneumoniae peritonitis and pneumonia) 4
• Screen for latent infections before immunosuppression 1

Alternative First-Line Therapy

Cyclosporine as alternative to corticosteroids:

• Indicated when corticosteroids are contraindicated (uncontrolled diabetes risk, severe osteoporosis, psychiatric disease) 1, 2, 6
• Starting dose: 2-3 mg/kg/day divided twice daily, titrate to 4-5 mg/kg/day 2, 3
• Target trough level: 100-175 ng/mL 2, 3
• Cyclosporine preferred over tacrolimus due to lower risk of precipitating diabetes 3, 6

Monitoring and Follow-Up

Initial phase (first 2-4 months):

• Assess proteinuria every 2-4 weeks using spot UPCR or 24-hour collection 3
• Monitor serum albumin, renal function, and lipid profile 3
• Watch for steroid-related adverse effects (hyperglycemia, hypertension, weight gain, mood changes) 7

Long-term monitoring:

• Clinic visits every 3-6 months for lifelong surveillance 3
• 85-90% of steroid-responsive patients will relapse but remain steroid-sensitive 4
• Only 1-3% of initially steroid-sensitive patients become steroid-resistant 4

Common Pitfalls to Avoid

1. Starting ACE inhibitors/ARBs immediately in acute-onset nephrotic syndrome can precipitate AKI in MCD patients 1
2. Performing kidney biopsy in typical pediatric cases (age 1-10 years) delays treatment unnecessarily 3, 4, 5
3. Routine albumin infusions without clinical hypovolemia waste resources and provide no benefit 2, 4, 8
4. Premature steroid tapering (<6 months total duration) increases relapse risk 2, 6
5. Failing to assess thromboembolism risk when albumin <2.0 g/dL can result in life-threatening pulmonary embolism (17-28% risk) 2, 6, 9